Two Northern Ireland deaths flagged in safety monitoring of GLP-1 weight‑loss drugs
Two deaths in Northern Ireland were reported to the MHRA as potential adverse reactions to GLP-1 weight‑loss drugs (Mounjaro and Wegovy), part of more than 500 suspected adverse drug reactions in NI over the last two years. The MHRA cautions that such reports do not prove causation and could involve underlying conditions or coincidences; the fatalities were a man in his 40s and a woman in her 60s, with six pancreatitis cases recorded in 2024–25. Most reports came from healthcare professionals; regulators and drugmakers emphasise ongoing monitoring and safety.
